{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:30:32Z","timestamp":1793784632871,"version":"4.6.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radionuclide SPECT\/computed tomography (CT) is standard for diagnosing transthyretin cardiac amyloidosis (ATTR-CM), but the prognostic value of quantitative metrics remains incompletely defined. We investigated their prognostic utility and additive value beyond existing staging systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective study of patients undergoing technetium-99m-pyrophosphate (PYP) SPECT\/CT, including consecutive clinically referred patients (October 2023 to 2024) and trial participants with positive scans from January 2022. Myocardial PYP was quantified using standardized uptake values (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      and SUV\n                      <jats:sub>max<\/jats:sub>\n                      ) and volumetric measures [percent injected dose (%ID), cardiac amyloid activity (CAA)]. Major adverse cardiovascular events (MACEs) comprised heart failure hospitalization or death. Cox and Kaplan\u2013Meier analyses assessed associations; likelihood ratio testing and change in area under the curve (AUC) evaluated the additive prognostic value to existing staging systems.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 43 patients with ATTR-CM, 16 experienced MACE over a median 518 days. AUCs ranged from 0.74 to 0.88 at 3 months and 0.56\u20130.62 at 12 months. All variables trended toward association with MACE: SUV\n                      <jats:sub>mean<\/jats:sub>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02), SUV\n                      <jats:sub>max<\/jats:sub>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03), %ID (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.06), and CAA (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.06). After age adjustment, cut-points for SUV\n                      <jats:sub>max<\/jats:sub>\n                      (5.8) and SUV\n                      <jats:sub>mean<\/jats:sub>\n                      (3.5) remained associated with MACE. Adding imaging variables to the National Amyloidosis Centre and Columbia staging systems did not significantly improve prognostic accuracy (\u0394\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      : 0.40\u20132.48,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.11\u20130.53). Interobserver reproducibility was high (intraclass correlation coefficients = 0.89\u20130.99).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Quantitative Tc-99m\u2013PYP SPECT\/CT metrics were associated with short-term outcomes in ATTR-CM, but did not improve established staging systems. Findings are hypothesis-generating and require validation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002199","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:00:13Z","timestamp":1783933213000},"page":"1297-1308","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative single photon emission computed tomography\/computed tomography of Tc-99m-pyrophosphate scans: metrics for short-term risk stratification in transthyretin cardiac amyloidosis"],"prefix":"10.1097","volume":"47","author":[{"given":"Mitchell","family":"Pleasure","sequence":"first","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace L.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Castillo","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"DeLuca","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Kinkhabwala","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Chernovolenko","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"},{"name":"Department of Radiology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Elias","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"},{"name":"Department of Biomedical Informatics, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Poterucha","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"},{"name":"Division of Echocardiography and Cardiac Imaging, Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Wats","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Brailovsky","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-9278","authenticated-orcid":false,"given":"Andrew J.","family":"Einstein","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine"},{"name":"Department of Radiology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review.","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1007\/s12350-023-03297-1","article-title":"Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis.","volume":"30","author":"Ahluwalia","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association.","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s12350-022-03133-y","article-title":"(99m)Tc-PYP SPECT and SPECT\/CT quantitation for diagnosing cardiac transthyretin amyloidosis.","volume":"30","author":"Nichols","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1007\/s12350-023-03214-6","article-title":"Attacking the Achilles heel of cardiac amyloid nuclear scintigraphy: how to reduce equivocal and false positive studies.","volume":"30","author":"Al Taha","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","article-title":"DPD quantification in cardiac amyloidosis.","volume":"13","author":"Scully Paul","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.123.266926","article-title":"Prognostic value of [(99m)Tc]Tc-DPD quantitative SPECT\/CT in patients with suspected and confirmed amyloid transthyretin-related cardiomyopathy and preserved left ventricular function.","volume":"65","author":"Caobelli","year":"2024","journal-title":"J Nucl Med"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ehjci\/jeae295","article-title":"Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis.","volume":"26","author":"Rettl","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"102275","DOI":"10.1016\/j.nuclcard.2025.102275","article-title":"Prognostic value of 99mtechnetium-pyrophosphate single-photon emission computed tomography visual grade in patients with transthyretin cardiac amyloidosis on stabilization therapy.","volume":"51","author":"Romero Pab\u00f3n","year":"2025","journal-title":"J Nucl Cardiol"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1007\/s12350-023-03256-w","article-title":"Comparison of cardio-focal and chest reconstruction of technetium-99m pyrophosphate scintigraphy for diagnosis of transthyretin cardiac amyloidosis: a quality assurance study.","volume":"30","author":"Akincioglu","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"e030512","DOI":"10.1161\/JAHA.123.030512","article-title":"Use of technetium-99m-pyrophosphate single-photon emission computed tomography\/computed tomography in monitoring therapeutic changes of eplontersen in patients with hereditary transthyretin amyloid cardiomyopathy.","volume":"13","author":"Yu","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy.","volume":"24","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis.","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis.","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamacardio.2025.4591","article-title":"Detecting transthyretin cardiac amyloidosis with artificial intelligence: a nonrandomized clinical trial.","volume":"11","author":"Jain","year":"2025","journal-title":"JAMA Cardiol"},{"key":"R17-20261104","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamacardio.2025.2948","article-title":"Transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure.","volume":"10","author":"Ruberg","year":"2025","journal-title":"JAMA Cardiol"},{"key":"R18-20261104","first-page":"e000029","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2 \u2013 evidence base and standardized methods of imaging.","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"R19-20261104","doi-asserted-by":"crossref","first-page":"e019375","DOI":"10.1161\/CIRCIMAGING.125.019375","article-title":"Imaging time, quantitation, and the evolving practice of cardiac amyloid radionuclide imaging.","volume":"19","author":"Sperry","year":"2026","journal-title":"Circ Cardiovasc Imaging"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves.","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinf"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse.","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT.","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1007\/s00259-025-07294-z","article-title":"A quantitative SPECT\/CT metric for diagnosing transthyretin cardiac amyloidosis: multicenter study on biopsy-confirmed cases.","volume":"52","author":"Takaishi","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-20261104","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s12350-021-02563-4","article-title":"Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis.","volume":"28","author":"Miller","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"R27-20261104","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2967\/jnumed.124.267542","article-title":"Deep learning-enabled quantification of (99m)Tc-pyrophosphate SPECT\/CT for cardiac amyloidosis.","volume":"65","author":"Miller","year":"2024","journal-title":"J Nucl Med"},{"key":"R28-20261104","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s11604-021-01221-6","article-title":"Usefulness of quantitative (99m)Tc-pyrophosphate SPECT\/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis.","volume":"40","author":"Ogasawara","year":"2022","journal-title":"Jpn J Radiol"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"102573","DOI":"10.1016\/j.nuclcard.2025.102573","article-title":"Artificial intelligence-driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: correlation with multimodality imaging and outcomes.","volume":"56","author":"Miller","year":"2026","journal-title":"J Nucl Cardiol"},{"key":"R30-20261104","doi-asserted-by":"crossref","first-page":"e003356","DOI":"10.1161\/CIRCGEN.121.003356","article-title":"Prevalence and outcomes of p.Val142Ile TTR amyloidosis cardiomyopathy: a systematic review.","volume":"14","author":"Chandrashekar","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"R31-20261104","doi-asserted-by":"crossref","first-page":"102056","DOI":"10.1016\/j.nuclcard.2024.102056","article-title":"Single-photon emission computed tomography\/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis.","volume":"42","author":"Godoy-Rivas","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"R32-20261104","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00259-024-06981-7","article-title":"Clinical significance of quantitative assessment of right ventricular amyloid burden with [99mTc]Tc-DPD SPECT\/CT in transthyretin cardiac amyloidosis.","volume":"52","author":"Zhao","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R33-20261104","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcmg.2022.12.016","article-title":"Tafamidis treatment decreases 99mtc-pyrophosphate uptake in patients with hereditary Ala97Ser transthyretin amyloid cardiomyopathy.","volume":"16","author":"Yu","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"R34-20261104","doi-asserted-by":"crossref","first-page":"e0301756","DOI":"10.1371\/journal.pone.0301756","article-title":"Preclinical evaluation of Tc-99m p5\u2009+\u200914 peptide for SPECT detection of cardiac amyloidosis.","volume":"19","author":"Kennel","year":"2024","journal-title":"PLoS One"},{"key":"R35-20261104","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12350-022-02988-5","article-title":"Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis.","volume":"30","author":"Avalon","year":"2023","journal-title":"J Nucl Cardiol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:00:14Z","timestamp":1793782814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002199","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"2026-05-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}